Gary R Lichtenstein1, Brian G Feagan1, Uma Mahadevan1, Bruce A Salzberg1, Wayne Langholff1, James G Morgan1, Michael Safdi1, Riikka Nissinen1,1, François Taillard1, William J Sandborn1, Russell D Cohen1. 1. Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Robarts Clinical Trials, Western University, London, ON, Canada. University of California, San Francisco, CA, USA. Atlanta Gastroenterology Specialists, Atlanta, GA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Formerly an employee of Janssen Scientific Affairs, LLC, Horsham, PA, USA. Janssen-Cilag Oy, Espoo, Finland. Formerly an employee of Janssen Biologics BV, Leiden, The Netherlands. Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA. Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA. Some of the data in this article were presented at United European Gastroenterology Week 2013 in Berlin, Germany.
Abstract
OBJECTIVES: We described pregnancy outcomes in Crohn's disease (CD) patients enrolled in the TREAT Registry who received infliximab before, or during pregnancy and those not treated with infliximab or any biologic agent. METHODS: In the TREAT Registry (1999-2012), pregnancy outcomes were analyzed from maternal and paternal patients exposed to infliximab ≤365 days (gestational exposure), >365 days (pre-gestational exposure) of pregnancy outcome or without infliximab exposure (non-biologic exposed). "Healthy infants" were defined as those with no congenital abnormalities, neonatal complications (e.g., jaundice, prematurity, heart murmur, cortical vision/fine motor delay, cardiac failure, hemophilia, or torticollis), prolonged hospitalization, or those who received no special treatment. Disease activity and concomitant medications were also evaluated. RESULTS: Overall, 92.3% (324/351) of pregnancies had known outcomes. The majority of both maternal pregnancies (92.6, 91.2, and 87.8%) and partner outcomes (92.7, 93.8, and 91.7%) resulted in live births of healthy infants across gestational, pre-gestational, and non-biologic exposure groups, respectively. Among these, rates of neonatal complications were low for both maternal (6.2, 7.0, and 8.5%), and partner outcomes (4.9, 0, and 0%) in gestational, pre-gestational, and non-biologic exposure groups, respectively. Among maternal pregnancies, numerically higher rates of spontaneous abortions were observed for the gestational exposure group than for the pre-gestational or non-biologic exposed groups. CONCLUSIONS: The clinical condition of infants born to women with gestational infliximab exposure was similar to those without exposure. Although a lower live birth rate was reported among infliximab-exposed women, these patients had more severe CD and were more likely to have been exposed to immunosuppressives.
OBJECTIVES: We described pregnancy outcomes in Crohn's disease (CD) patients enrolled in the TREAT Registry who received infliximab before, or during pregnancy and those not treated with infliximab or any biologic agent. METHODS: In the TREAT Registry (1999-2012), pregnancy outcomes were analyzed from maternal and paternal patients exposed to infliximab ≤365 days (gestational exposure), >365 days (pre-gestational exposure) of pregnancy outcome or without infliximab exposure (non-biologic exposed). "Healthy infants" were defined as those with no congenital abnormalities, neonatal complications (e.g., jaundice, prematurity, heart murmur, cortical vision/fine motor delay, cardiac failure, hemophilia, or torticollis), prolonged hospitalization, or those who received no special treatment. Disease activity and concomitant medications were also evaluated. RESULTS: Overall, 92.3% (324/351) of pregnancies had known outcomes. The majority of both maternal pregnancies (92.6, 91.2, and 87.8%) and partner outcomes (92.7, 93.8, and 91.7%) resulted in live births of healthy infants across gestational, pre-gestational, and non-biologic exposure groups, respectively. Among these, rates of neonatal complications were low for both maternal (6.2, 7.0, and 8.5%), and partner outcomes (4.9, 0, and 0%) in gestational, pre-gestational, and non-biologic exposure groups, respectively. Among maternal pregnancies, numerically higher rates of spontaneous abortions were observed for the gestational exposure group than for the pre-gestational or non-biologic exposed groups. CONCLUSIONS: The clinical condition of infants born to women with gestational infliximab exposure was similar to those without exposure. Although a lower live birth rate was reported among infliximab-exposed women, these patients had more severe CD and were more likely to have been exposed to immunosuppressives.
Authors: Tim Raine; Maria Angeliki Gkini; Peter M Irving; Arvind Kaul; Eleanor Korendowych; Philip Laws; Amy C Foulkes Journal: BioDrugs Date: 2021-02-26 Impact factor: 5.807
Authors: Walter Reinisch; Krisztina Gecse; Jonas Halfvarson; Peter M Irving; Jørgen Jahnsen; Laurent Peyrin-Biroulet; Gerhard Rogler; Stefan Schreiber; Silvio Danese Journal: Inflamm Bowel Dis Date: 2021-01-01 Impact factor: 5.325
Authors: L F Perez-Garcia; R J E M Dolhain; S Vorstenbosch; W Bramer; E van Puijenbroek; J M W Hazes; B Te Winkel Journal: Hum Reprod Update Date: 2020-11-01 Impact factor: 15.610
Authors: Ana-Marija Grišić; Maria Dorn-Rasmussen; Bella Ungar; Jørn Brynskov; Johan F K F Ilvemark; Nils Bolstad; David J Warren; Mark A Ainsworth; Wilhelm Huisinga; Shomron Ben-Horin; Charlotte Kloft; Casper Steenholdt Journal: United European Gastroenterol J Date: 2021-02-11 Impact factor: 4.623